Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkem LaboratoriesNSE:ALKEM +0.62%97 PB Ratio is 4.85 as of Jul. 15, 2026, which is 2% above its 10-year median of 4.76. GuruFocus rates NSE:ALKEM with a GF Score™ of 97/100 and a GF Value™ of ₹6,104.31 (Fairly Valued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Alkem Laboratories ranks worse than 80.69% on this metric.
Alkem Laboratories Ltd stock PB Ratio (=4.9) is close to 2-year low of 4.53.
The historical rank and industry rank for Alkem Laboratories's PB Ratio or its related term are showing as below:
NSE:ALKEM'
s PB Ratio Range Over the Past 10 Years
Min: 3.67 Med: 4.76 Max: 6.44
Current: 4.84
During the past 13 years, Alkem Laboratories's highest PB Ratio was 6.44. The lowest was 3.67. And the median was 4.76.
NSE:ALKEM's PB Ratio is ranked worse than 80.69% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs NSE:ALKEM: 4.84
During the past 12 months, Alkem Laboratories's average Book Value Per Share Growth Rate was 15.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 15.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Alkem Laboratories was 25.30% per year. The lowest was 11.30% per year. And the median was 15.55% per year.
Back to Basics: PB Ratio
Alkem Laboratories (NSE:ALKEM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alkem Laboratories PB Ratio Related Terms
Alkem Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Alkem Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkem Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alkem Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alkem Laboratories (NSE:ALKEM) has a PB Ratio of 4.85 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alkem Laboratories and its competitors. This is near median its historical median of 4.76. Over the past decade, Alkem Laboratories' PB Ratio has ranged from 3.67 to 6.44. According to the industry distribution chart, Alkem Laboratories ranks #744 out of 922 companies in the Drug Manufacturers industry, placing it in the top 80.7%.
Is Alkem Laboratories' PB Ratio too high?
Alkem Laboratories' current PB Ratio of 4.85 is near median its 10-year median of 4.76. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 6.44. The Drug Manufacturers industry median PB Ratio is 1.92. Alkem Laboratories' value of 4.85 is 152.6% above this industry median. Based on the distribution chart, Alkem Laboratories ranks #744 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alkem Laboratories has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #744 out of 922 companies for PB Ratio. This places Alkem Laboratories in the lower half of its industry. The industry median PB Ratio is 1.92. Alkem Laboratories' value of 4.85 is 152.6% above this benchmark. Historically, Alkem Laboratories' own PB Ratio has ranged from 3.67 to 6.44 over the past decade. While the company's 10-year median is 4.76 vs. the industry median of 1.92, Alkem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current PB Ratio of 4.85 is 152.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alkem Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current PB Ratio is 4.85, which is near median its own 10-year median of 4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,104.31, compared to a current price of ₹5,601.50 — trading 8.2% below its estimated fair value. The current PB Ratio is 4.85, which is near median its 10-year median of 4.76 and 152.6% above the Drug Manufacturers industry median of 1.92. Alkem Laboratories' overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current PB Ratio is 4.85 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?
Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued.
The current stock price of ₹5,601.50 is trading 8.2% below its estimated GF Value™ of ₹6,104.31.
GuruFocus considers Alkem Laboratories to be Fairly Valued.
Key valuation signals for NSE:ALKEM:
PB Ratio: 4.85 (near median its 10-year median of 4.76)
GF Value™: ₹6,104.31 vs. price of ₹5,601.50 (8.2% below fair value)
Industry Position: 152.6% above the Drug Manufacturers median (#744 of 922)
No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
97GF Score
Get the complete analysis for NSE:ALKEM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALKEM has been successfully added to your 
